Sobi showcases commitment to haemophilia community at EAHAD 2021
Sobi™ will present data at the 14th European Association of Haemophilia and Allied Disorders (EAHAD) virtual conference from 3-5 February 2021, showing evidence further supporting the safety, efficacy and long-term benefits of its Fc-fusion extended half-life (EHL) products for the treatment of haemophilia. The data to be presented also supports Sobi’s ongoing commitment to liberating life for people with haemophilia, with a new product candidate in development. Sobi will also host a satellite symposium exploring the full potential of proactive haemophilia